Canaccord Genuity Initiates Coverage On PagerDuty with Buy Rating, Announces Price Target of $32
Canaccord Genuity analyst Kingsley Crane initiates coverage on PagerDuty (NYSE:PD) with a Buy rating and announces Price Target of $32.
Canaccord Genuity Initiates Coverage On Elastic with Buy Rating, Announces Price Target of $100
Canaccord Genuity analyst Kingsley Crane initiates coverage on Elastic (NYSE:ESTC) with a Buy rating and announces Price Target of $100.
Canaccord Genuity Initiates Coverage On JFrog with Buy Rating, Announces Price Target of $30
Canaccord Genuity analyst Kingsley Crane initiates coverage on JFrog (NASDAQ:FROG) with a Buy rating and announces Price Target of $30.
Needham Sees GitLab Increasingly Becoming Center Of Gravity For Organizational Software Innovation
Needham analyst Mike Cikos initiated coverage on GitLab Inc (NASDAQ:GTLB) with a Buy rating with a price target of $70 (21% upside).…
Needham Sees Potential In Duolingo To Spearhead $115B Language Learning Market
Needham analyst Ryan MacDonald initiated coverage on Duolingo, Inc (NASDAQ:DUOL) with a Buy rating and a price target of $115. MacDonald acknowledges that…
Roth Capital Initiates Coverage On Kalera with Buy Rating, Announces Price Target of $6
Roth Capital analyst Brian White initiates coverage on Kalera (NASDAQ:KAL) with a Buy rating and announces Price Target of $6.
Needham Initiates Coverage On Duolingo with Buy Rating, Announces Price Target of $115
Needham analyst Ryan MacDonald initiates coverage on Duolingo (NASDAQ:DUOL) with a Buy rating and announces Price Target of $115.
Needham Initiates Coverage On GitLab with Buy Rating, Announces Price Target of $70
Needham analyst Mike Cikos initiates coverage on GitLab (NASDAQ:GTLB) with a Buy rating and announces Price Target of $70.
Chardan Capital Initiates Coverage On EyePoint Pharmaceuticals with Buy Rating, Announces Price Target of $21
Chardan Capital analyst Daniil Gataulin initiates coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy rating and announces Price Target of $21.